According to a recent LinkedIn post from Xeltis, the company’s team participated in the Charing Cross Symposium in London, engaging with specialists in the global vascular community. The post highlights new 12‑month, multi‑center EU pivotal trial data for its aXess vascular access conduit in 120 complex patients, presented by Dr. Augusto Ministro.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post quotes Dr. Ministro describing the conduit’s behavior over time as increasingly similar to a “living vessel,” with ultrasound suggesting progressive compliance as tissue remodels. This characterization, if supported by longer‑term outcomes and peer‑reviewed evidence, could position aXess as a differentiated solution in vascular access for dialysis patients.
The post also notes strong audience engagement with a session led by Prof. Frans Moll on next‑generation bioabsorbable conduits for bypass, reflecting continued interest in regenerative vascular technologies. For investors, this interest may signal a favorable reception among clinicians, an important factor for future adoption and reimbursement discussions.
Xeltis’s commentary from the event suggests that the potential of aXess to reduce reinvention procedures and catheter dependency drew notable attention at its booth. If these clinical and workflow benefits are validated and maintained post‑CE mark, they could support a stronger value proposition, improve market penetration prospects in Europe, and enhance the company’s competitive position in the vascular access segment.